<DOC>
	<DOC>NCT00712257</DOC>
	<brief_summary>A Multicenter study to evaluation the safety and performance of Spectranetics Laser with Adjunct PTA and Gore Viabahn Endoprosthesis for the Treatment of SFA Instent Restenosis</brief_summary>
	<brief_title>Study to Evaluate the Safety and Performance of Spectranetics Laser w/Adjunct PTA and Gore Viabahn Endoprosthesis for Treatment of SFA Instent Restenosis</brief_title>
	<detailed_description />
	<mesh_term>Heparin</mesh_term>
	<criteria>Subject or subject's legal representative informed of the study nature. Subject understands the duration of the study and its follow up visit requirements. Intermittent claudication extending through critical limb ischemia meeting a Rutherford 25 category. Subject able to walk unassisted. Female subjects of childbearing potential must have a negative serum pregnancy test 7 days prior to treatment. Life expectancy less than 12 months Myocardial infarction less than 3 months prior to procedure Known allergies or sensitivities to heparin, aspirin, other anticoagulant/antiplatelet therapies and nitinol. Known allergy to contrast media that cannot adequately be premedicated prior to study procedure. Uncontrolled hypercoagulability</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>89 Years</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>treatment of superficial femoral artery instent restenosis</keyword>
</DOC>